SINGAPORE, Oct 21 (Bernama-GLOBE NEWSWIRE) -- Aquient, a leading digital customer experience agency in Asia, is excited to announce that it has received Gold Consulting Partner status from Salesforce. The company has become a go-to partner in Asia for multi-cloud strategy and deployment.
Achieving Salesforce Gold Consulting Partner Status requires a company to meet several milestones to demonstrate an exceptional level of expertise and client success. These requirements include client engagement, employee expertise, and high customer satisfaction.
"It's a pleasure to be recognised for our efforts by Salesforce. I am immensely grateful for the dedication of our team, their contributions toward this advancement and their focus to allow us to achieve this milestone in such a short period of time. The opportunities for top-tier, strategic partners in the Salesforce partner ecosystem are incredible, and we look forward to continued growth," says Aquient CEO, Jimmy Storrier.
Founded in 2018 and with offices in Singapore, Hong Kong, Philippines and Bangkok, Aquient has invested heavily in quickly expanding its capabilities across the Salesforce cloud ecosystem to build and deliver world-class solutions. The addition of several high-profile customers has driven the rapid expansion of the Aquient team across Asia. This growth includes hiring of senior level Technical Architects, Engagement Managers, and Customer Experience Consultants among others. Storrier noted that the 2020 plans for hiring at Aquient in Asia could be as high as 30 additional team members, including expansion into the high growth markets of Indonesia and Vietnam.
Storrier also added, "It appears our outcomes-based approach is working. While we have a deep commitment to the power of the Salesforce platform, we also partner closely with our clients to digitally transform their businesses, providing them with high quality expertise and guidance and delivering experiences that drive loyalty, engagement and revenue. Being recognised as a Gold Consulting Partner is a testament to our commitment to our customers' success."
Aquient has grown a portfolio of more than 20 clients in the past 12 months, and focuses on helping companies optimise their overall end-user customer experience using data, strategy and technology.
About Aquient
Aquient Pte Ltd is a digital customer experience agency that is quickly growing and expanding its service and product offering. It holds vendor partnership status as a Salesforce Gold Consulting Partner and Google Cloud Platform Partner. Aquient covers all aspects of customer experience, including cloud platform implementation and integration, strategy, analytics, data science, marketing automation, digital acceleration, web and mobile platform development and creative content.
SOURCE Aquient
Monday, October 21, 2019
ADX Group updates IPO progress, new cyber security offerings
KUALA LUMPUR, Oct 21 -- ADX Group (ADX), a global technology company has announced progress towards its initial public offering (IPO).
ADX founder, Steven M. Renner said: “ADX has formally engaged independent auditors to commence a pre-IPO audit, and our NASDAQ IPO remains on track for early 2022.”
Renner commented a day before the company’s 11th annual Autumn Conference in Jeju Island, South Korea.
More than 700 ADX sales consultants heard updates on the company’s IPO, new ADX Cyber Security Services (including ADX Mail, ADX Cloud, ADX VPN and WebCast.Pro secure conferencing services), YouChat secure mobile messaging services, popular AWL Cloud Hosting Services and advances in ADX Mobile Games.
“ADX’s advances in artificial intelligence, machine learning, deep learning and blockchain technology as a service have significantly enhanced ADX’s AWL Cloud Services end-user accounts,” said Renner.
“Building upon AWL’s momentum, ADX Cyber Security Services enables simple and effective safeguarding of individual freedoms and privacy, which are increasingly under threat.”
-- BERNAMA
-- BERNAMA
Saturday, October 19, 2019
PATIENT-DERIVED TUMOR ORGANOID DRUG DEVELOPMENT PLATFORM LAUNCHED
Industry Leading Innovation Promises to Disrupt Traditional Drug Discovery
SAN DIEGO, Oct 18 (Bernama-GLOBE NEWSWIRE) -- Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery.
The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio’s uniquely-characterized library of 2500+ patient-derived xenograft (PDX) models.
PDXOs are biologically equivalent to highly predictive in vivo PDX models, both being cancer stem cell driven disease models. PDXOs bring the added benefits of speed and scalability inherent to in vitro systems which are ideal for high-throughput, large-scale screens and simultaneous testing of multiple combination strategies.
These 3D in vitro models have been developed using best-in-class Hubrecht Organoid Technology (HUB) protocols, originating from the Clevers lab, guaranteeing robustness and proven translatability. CrownBio has an exclusive license from HUB to provide preclinical oncology drug development and validation services using HUB’s Organoid Technology.
The initial launch of PDXO models includes more than 10 cancer types. Phase 2 of the platform will see HUB patient-derived organoids (PDO) available exclusively from CrownBio in Q1 2020.
“At CrownBio, we’ve pioneered the development of patient-derived models,” said Henry Li, PhD chief scientific officer at CrownBio. “Our new library of well-characterized and annotated organoids with matched in vivo PDX models offers an unprecedented translational workflow for preclinical drug discovery. For the first time, a truly seamless transition from in vitro to in vivo is possible. Through our model annotation, there’s also the opportunity for automated biomarker discovery to improve our ability to predict patient response.”
Further benefits of patient-relevant PDXO models include preserving the genomic, morphological, and pathophysiological identity of their parental PDX tumors. PDXO and PDX also display similar pharmacology profiles.
“We are delighted to see HUB Organoid technology being successfully applied to the development of PDX-derived organoids and being made available to the broader industry by CrownBio,” said HUB CEO Rob Vries, PhD. “This pioneering system provides access to an expanded library of patient-derived in vitro and in vivo models effectively bringing a wider cancer patient population into the lab.”
HUB Organoids are already a proven preclinical oncology tool providing consistent and stable growth through passages and superior quality assay readouts compared to standard 2D and 3D systems. Organoid biobanks can also be established without losing original identity for follow on or repeat studies.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
- https://www.crownbio.com
- https://www.jsrlifesciences.com
About HUB
Hubrecht Organoid Technology (HUB) is an organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘mini-organs’ (HUB Organoids) from tissues of patients with various diseases. The organoids, which are part of the HUB biobanks, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. HUB offers licenses to its patented HUB Organoid Technology and access to organoids from the HUB biobank for preclinical drug screening, discovery, development and validation. In addition, HUB is performing clinical studies to validate the technology’s use as a companion diagnostic. More info at www.hub4organoids.eu.
http://mrem.bernama.com/viewsm.php?idm=35851
SAN DIEGO, Oct 18 (Bernama-GLOBE NEWSWIRE) -- Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery.
The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio’s uniquely-characterized library of 2500+ patient-derived xenograft (PDX) models.
PDXOs are biologically equivalent to highly predictive in vivo PDX models, both being cancer stem cell driven disease models. PDXOs bring the added benefits of speed and scalability inherent to in vitro systems which are ideal for high-throughput, large-scale screens and simultaneous testing of multiple combination strategies.
These 3D in vitro models have been developed using best-in-class Hubrecht Organoid Technology (HUB) protocols, originating from the Clevers lab, guaranteeing robustness and proven translatability. CrownBio has an exclusive license from HUB to provide preclinical oncology drug development and validation services using HUB’s Organoid Technology.
The initial launch of PDXO models includes more than 10 cancer types. Phase 2 of the platform will see HUB patient-derived organoids (PDO) available exclusively from CrownBio in Q1 2020.
“At CrownBio, we’ve pioneered the development of patient-derived models,” said Henry Li, PhD chief scientific officer at CrownBio. “Our new library of well-characterized and annotated organoids with matched in vivo PDX models offers an unprecedented translational workflow for preclinical drug discovery. For the first time, a truly seamless transition from in vitro to in vivo is possible. Through our model annotation, there’s also the opportunity for automated biomarker discovery to improve our ability to predict patient response.”
Further benefits of patient-relevant PDXO models include preserving the genomic, morphological, and pathophysiological identity of their parental PDX tumors. PDXO and PDX also display similar pharmacology profiles.
“We are delighted to see HUB Organoid technology being successfully applied to the development of PDX-derived organoids and being made available to the broader industry by CrownBio,” said HUB CEO Rob Vries, PhD. “This pioneering system provides access to an expanded library of patient-derived in vitro and in vivo models effectively bringing a wider cancer patient population into the lab.”
HUB Organoids are already a proven preclinical oncology tool providing consistent and stable growth through passages and superior quality assay readouts compared to standard 2D and 3D systems. Organoid biobanks can also be established without losing original identity for follow on or repeat studies.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
- https://www.crownbio.com
- https://www.jsrlifesciences.com
About HUB
Hubrecht Organoid Technology (HUB) is an organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘mini-organs’ (HUB Organoids) from tissues of patients with various diseases. The organoids, which are part of the HUB biobanks, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. HUB offers licenses to its patented HUB Organoid Technology and access to organoids from the HUB biobank for preclinical drug screening, discovery, development and validation. In addition, HUB is performing clinical studies to validate the technology’s use as a companion diagnostic. More info at www.hub4organoids.eu.
http://mrem.bernama.com/viewsm.php?idm=35851
Friday, October 18, 2019
MEGAZONE CLOUD, LG CNS PARTNERSHIP ACCELERATES DIGITAL TRANSFORMATION
KUALA LUMPUR, Oct 11 (Bernama) -- Megazone Cloud has signed a joint venture agreement with LG CNS, a subsidiary of LG Corporation based in Korea, to help companies with digital transformation including cloud migration and operation.
The combined experience and expertise will provide synergistic support for enterprises, from assessment and planning to development and operation.
Two partners will go through detailed operation planning together and expect to finalise setting up the new joint venture by year-end.
Both will also expand coverage to overseas markets to support ever-increasing global cloud service market.
Megazone Cloud chief executive officer, Max Joo Wan Lee said: “The combination of the core competencies of the two companies will enable us to offer a more reliable end-to-end cloud service.
“The two companies will forge ahead in the international cloud market of finance and public sectors.”
Gartner, the world’s leading research and advisory company, forecasts that the size of the international public cloud service market will reach US$249.8 billion by next year. (US$1 = RM4.18)
Megazone Cloud is one of the largest cloud managed service providers in the Asia Pacific region. Since 1998, the company has offered business-to-business IT services.
-- BERNAMA
The combined experience and expertise will provide synergistic support for enterprises, from assessment and planning to development and operation.
Two partners will go through detailed operation planning together and expect to finalise setting up the new joint venture by year-end.
Both will also expand coverage to overseas markets to support ever-increasing global cloud service market.
Megazone Cloud chief executive officer, Max Joo Wan Lee said: “The combination of the core competencies of the two companies will enable us to offer a more reliable end-to-end cloud service.
“The two companies will forge ahead in the international cloud market of finance and public sectors.”
Gartner, the world’s leading research and advisory company, forecasts that the size of the international public cloud service market will reach US$249.8 billion by next year. (US$1 = RM4.18)
Megazone Cloud is one of the largest cloud managed service providers in the Asia Pacific region. Since 1998, the company has offered business-to-business IT services.
-- BERNAMA
Informa Pharma Intelligence launches Citeline Engage solution
KUALA LUMPUR, Oct 11 -- Informa Pharma Intelligence has unveiled a new solution to optimise site selection and increase trial efficiencies to accelerate clinical trial timelines, enabling a faster path to market for drugs.
Citeline Engage is a first-to-market solution designed specifically to help optimise protocol development, site feasibility, and most importantly, increase physician engagement and drive patient awareness to support faster enrollment into clinical trials.
This solution is beneficial for contract research organisations and sponsors.
Informa Pharma Intelligence’s Citeline Engage utilises real-world data to offer the most efficient outreach services that allow customers to better recruit investigators and patients, optimise trial protocols and ignite awareness around trials.
Informa Pharma Intelligence, Vice-President (Product Development), Nicola Marlin said: “Citeline Engage empowers organisations to create and run the most efficient clinical trials possible through targeting and recruiting top tier investigators and select sites using unique online communities of verified healthcare professionals.
Informa Pharma Intelligence powers a full suite of analysis products to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
-- BERNAMA
Citeline Engage is a first-to-market solution designed specifically to help optimise protocol development, site feasibility, and most importantly, increase physician engagement and drive patient awareness to support faster enrollment into clinical trials.
This solution is beneficial for contract research organisations and sponsors.
Informa Pharma Intelligence’s Citeline Engage utilises real-world data to offer the most efficient outreach services that allow customers to better recruit investigators and patients, optimise trial protocols and ignite awareness around trials.
Informa Pharma Intelligence, Vice-President (Product Development), Nicola Marlin said: “Citeline Engage empowers organisations to create and run the most efficient clinical trials possible through targeting and recruiting top tier investigators and select sites using unique online communities of verified healthcare professionals.
Informa Pharma Intelligence powers a full suite of analysis products to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
-- BERNAMA
VIRGINIA'S PATH TO 55 FEET IS SET; FIRST PHASE OF DREDGING TO BEGIN IN JAN. 2020
NORFOLK, Va., Oct 11 (Bernama-BUSINESS WIRE) -- The effort to make The Port of Virginia® the deepest port on the U.S. East Coast begins by January 2020, following the finalization this week of a contract with the dredging firm that will build the project’s initial phase.
On Oct. 9, John F. Reinhart, CEO and executive director of the Virginia Port Authority, signed a contract with New Jersey-based Weeks Marine to begin construction.
The contract for the first phase is $78 million and the total cost of the project, including the preliminary engineering and design work, is $350 million. The work includes dredging the shipping channels to 55 feet – with deeper ocean approaches – and widening the channel to more than 1,400 feet in specific areas. When dredging is complete in 2024, the commercial channels serving the Norfolk Harbor will be able to simultaneously accommodate two, ultra-large container vessels.
“When the work is complete, Virginia will be the only East Coast port with the capability to handle the biggest container ships afloat today,” Reinhart said. “Our trade with Asia is expanding and the ships working the Asia-U.S. East Coast trade are growing to accommodate the volumes. We are following the ship orders that are being placed and in the next 10 years, the vessels coming to Virginia and the East Coast from Asia via the Suez Canal will be even bigger. We’ll be ready to accommodate their depth and land-side needs.”
The port is less than a year away from completing a $750 million expansion of its two primary container terminals. When complete, the port will have the capacity to handle 1 million additional containers per year.
“Virginia is well-positioned to be the premier gateway for trade on the East Coast,” Reinhart said. “We are building a world-class port and thinking long-term with a focus on productivity and service for decades to come.”
The Virginia Port Authority (VPA) is a political subdivision of the Commonwealth of Virginia. The VPA owns and through its private operating subsidiary, Virginia International Terminals, LLC (VIT), operates four general cargo facilities Norfolk International Terminals, Portsmouth Marine Terminal, Newport News Marine Terminal and the Virginia Inland Port in Warren County. The VPA leases Virginia International Gateway and Richmond Marine Terminal.
http://mrem.bernama.com/viewsm.php?idm=35779
On Oct. 9, John F. Reinhart, CEO and executive director of the Virginia Port Authority, signed a contract with New Jersey-based Weeks Marine to begin construction.
The contract for the first phase is $78 million and the total cost of the project, including the preliminary engineering and design work, is $350 million. The work includes dredging the shipping channels to 55 feet – with deeper ocean approaches – and widening the channel to more than 1,400 feet in specific areas. When dredging is complete in 2024, the commercial channels serving the Norfolk Harbor will be able to simultaneously accommodate two, ultra-large container vessels.
“When the work is complete, Virginia will be the only East Coast port with the capability to handle the biggest container ships afloat today,” Reinhart said. “Our trade with Asia is expanding and the ships working the Asia-U.S. East Coast trade are growing to accommodate the volumes. We are following the ship orders that are being placed and in the next 10 years, the vessels coming to Virginia and the East Coast from Asia via the Suez Canal will be even bigger. We’ll be ready to accommodate their depth and land-side needs.”
The port is less than a year away from completing a $750 million expansion of its two primary container terminals. When complete, the port will have the capacity to handle 1 million additional containers per year.
“Virginia is well-positioned to be the premier gateway for trade on the East Coast,” Reinhart said. “We are building a world-class port and thinking long-term with a focus on productivity and service for decades to come.”
The Virginia Port Authority (VPA) is a political subdivision of the Commonwealth of Virginia. The VPA owns and through its private operating subsidiary, Virginia International Terminals, LLC (VIT), operates four general cargo facilities Norfolk International Terminals, Portsmouth Marine Terminal, Newport News Marine Terminal and the Virginia Inland Port in Warren County. The VPA leases Virginia International Gateway and Richmond Marine Terminal.
http://mrem.bernama.com/viewsm.php?idm=35779
Subscribe to:
Posts (Atom)